GSK taps new MD Anderson institute in $335m OX40 antibody deal
This article was originally published in Scrip
Executive Summary
The University of Texas MD Anderson Cancer Center is continuing its legacy of licensing oncology discoveries to pharmaceutical companies via a collaboration with GlaxoSmithKline through which the cancer center may earn more than $335 million in upfront and milestone payments plus royalties on sales of therapeutic antibodies that activate OX40 receptors on the surface of T cells to mount an immune system attack.